Investigational drug · Phase 3
HLX15
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Newly Diagnosed Multiple Myeloma.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
10
Any phase or sponsor naming "HLX15"
First trial start
2025
Apr 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX15", any sponsor or status.
Conditions studied
As listed on its trial records.
- Newly Diagnosed Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX15" as an intervention, largest first.
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
- A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT06895512 · 386 participants (planned) · Start Apr 2025 · Primary completion Jul 2027
Drug: HLX15-IV; Darzalex · For: Newly Diagnosed Multiple Myeloma
Sites: Shanghai, China
Shanghai Henlius BiotechIndustry
NCT07477587 · 258 participants (planned) · Start May 25, 2026 · Primary completion May 25, 2027
Drug: HLX15-SC-Rd; US-DARZALEX FASPRO®-Rd · For: Multiple Myeloma (MM)
Sites: Springdale, Arkansas; Jacksonville, Florida; Margate, Florida · 84 sites in all
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male SubjectsPivotal-lookingCompleted
Shanghai Henlius BiotechIndustry
NCT05679258 · 172 participants · Start Jan 31, 2023 · Primary completion Mar 16, 2024
Drug: HLX15; US-sourced DARZALEX® and 2 more · For: Multiple Myeloma
Sites: Beijing, China; Nanjing, China
Mayo ClinicAcademic, hospital or other
NCT05898646 · 96 participants (planned) · Start Sep 6, 2023 · Primary completion Nov 30, 2029
Drug: Daratumumab · For: AL Amyloidosis
Sites: Scottsdale, Arizona; Rochester, Minnesota
- Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyActive, not recruiting
Mayo ClinicAcademic, hospital or other
NCT05392946 · 49 participants · Start Aug 11, 2022 · Primary completion Sep 18, 2026
Drug: Bortezomib; Daratumumab and 2 more · For: Plasma Cell Myeloma
Sites: Rochester, Minnesota
Mayo ClinicAcademic, hospital or other
NCT06785415 · 37 participants (planned) · Start Mar 18, 2025 · Primary completion Apr 1, 2031
Drug: Daratumumab; Dexamethasone and 2 more · For: Recurrent Multiple Myeloma
Sites: Rochester, Minnesota
- Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruiting
Mayo ClinicAcademic, hospital or other
NCT05497804 · 17 participants · Start Sep 22, 2022 · Primary completion Feb 12, 2026
Drug: Carfilzomib; Daratumumab and 2 more · For: ISS Stage III Plasma Cell Myeloma; Multiple Myeloma
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
Mayo ClinicAcademic, hospital or other
NCT06042725 · 16 participants · Start Apr 11, 2024 · Primary completion May 28, 2026
Drug: Daratumumab; Dexamethasone and 2 more · For: Multiple Myeloma
Sites: Rochester, Minnesota
City of Hope Medical CenterAcademic, hospital or other
NCT06287944 · 15 participants (planned) · Start Jul 1, 2025 · Primary completion May 19, 2029
Drug: Actinium Ac 225-DOTA-Daratumumab; Daratumumab and 5 more · For: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome
Sites: Duarte, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Newly Diagnosed Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.